Big Statin Benefit in CAD Patients with the Metabolic Syndrome
Just 28 nondiabetic CAD patients with the metabolic syndrome needed to be treated with 80-mg atorvastatin to prevent 1 major adverse event over 5 years, according to a post hoc analysis of the TNT trial.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)